We are live on
!
Find out more
Royalty Pharma
RPRX
RPRX
326 hedge funds and large institutions have $9.32B invested in Royalty Pharma in 2023 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 139 increasing their positions, 107 reducing their positions, and 51 closing their positions.
New
Increased
Maintained
Reduced
Closed
313% more call options, than puts
Call options by funds: $21.9M | Put options by funds: $5.29M
30% more repeat investments, than reductions
Existing positions increased: 139 | Existing positions reduced: 107
3.26% more ownership
Funds ownership: 68.1% → 71.36% (+3.3%)
3% less funds holding
Funds holding: 335 → 326 (-9)
12% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 51
14% less capital invested
Capital invested by funds: $10.9B → $9.32B (-$1.56B)
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
Holders
326
Holders Change
-9
Holders Change %
-2.69%
% of All Funds
5.12%
Holding in Top 10
8
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-20%
% of All Funds
0.13%
New
45
Increased
139
Reduced
107
Closed
51
Calls
$21.9M
Puts
$5.29M
Net Calls
+$16.6M
Net Calls Change
-$18.1M
Top Buyers
| 1 |
SVCF
Silicon Valley Community Foundation
Mountain View,
California
|
+$532M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$47.6M |
| 3 |
Goldman Sachs
New York
|
+$45.5M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$38.4M |
| 5 |
Two Sigma Investments
New York
|
+$32.4M |
